RECRUITING

Identify microRNAs in Cachexia in Pancreatic Carcinoma

Conditions

Resectable Pancreatic Adenocarcinoma pancreatic cancer cachexia microRNA mRNA PDAC

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this study is to determine the proportion of pancreatic patients who experience weight loss and cachexia, and to identify any differences in the genes between patient groups.

Official Title

Pilot Trial to Identify microRNAs in Cachexia in Patients With Pancreatic Carcinoma

Quick Facts

Study Start:2022-12-07

Study Completion:2028-01-01

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT05275075

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
1. Male or female patient, who is ≥ 18 years old at the time of informed consent. 2. Patients with operable pancreatic tumors diagnosed in the last 12 months prior to consent with clinical discretion or pathology confirmed as adenocarcinoma. 3. Patient has stage I or higher disease who is considered a candidate for surgical resection of pancreatic cancer, with or without neoadjuvant chemotherapy. 4. Ability to provide written informed consent and HIPAA authorization.	1. Patients with pancreatic adenocarcinoma who do not meet the criteria for surgical resection. 2. Patient has cancer diagnosis other than primary pancreatic adenocarcinoma.

Inclusion Criteria

Exclusion Criteria

1. Male or female patient, who is ≥ 18 years old at the time of informed consent.
2. Patients with operable pancreatic tumors diagnosed in the last 12 months prior to consent with clinical discretion or pathology confirmed as adenocarcinoma.
3. Patient has stage I or higher disease who is considered a candidate for surgical resection of pancreatic cancer, with or without neoadjuvant chemotherapy.
4. Ability to provide written informed consent and HIPAA authorization.

1. Patients with pancreatic adenocarcinoma who do not meet the criteria for surgical resection.
2. Patient has cancer diagnosis other than primary pancreatic adenocarcinoma.

Contacts and Locations

Study Contact

Lead Nurse

CONTACT

405.271.8777

scc-iit-office@ouhsc.edu

Principal Investigator

Ajay Jain, MD

PRINCIPAL_INVESTIGATOR

University of Oklahoma Stephenson Cancer Center

Study Locations (Sites)

Stephenson Cancer Center

Oklahoma City, Oklahoma, 73117

United States

Collaborators and Investigators

Sponsor: University of Oklahoma

Ajay Jain, MD, PRINCIPAL_INVESTIGATOR, University of Oklahoma Stephenson Cancer Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2022-12-07

Study Completion Date2028-01-01

Study Record Updates

Study Start Date2022-12-07

Study Completion Date2028-01-01

Terms related to this study

Keywords Provided by Researchers

pancreatic cancer
cachexia
microRNA
mRNA
PDAC

Additional Relevant MeSH Terms

Resectable Pancreatic Adenocarcinoma